Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours

Clinical and Experimental Immunology

Volumn 110, Issue 2, 1997, Pages 303-309

  Tomokuni, A ^a   Aikoh, T ^a   Matsuki, T ^a   Isozaki, Y ^a   Otsuki, T ^a   Kita, S ^a   Ueki, H ^a   Kusaka, M ^b   Kishimoto, T ^c   Ueki, A ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kusaka Hospital   (Japan)

^c OKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

Apoptosis; Autoimmunity; Membranous Fas; Silicosis; Soluble Fas

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SILICOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 9844264856     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1997.tb08332.x     Document Type: Article

References (25)

1. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62.
2. Jodo S, Kobayashi N, Kayagaki N et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107:89-95.
3. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhaematopoietic human malignancy. Cancer Res 1996; 56:3870-4.
4. Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
5. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969-76.
6. + T cells. Nature 1995; 376:181-3.
7. Haustein UF, Ziegler V, Herrmann K et al. Silica-induced scleroderma. J Am Acad Dermatol 1990; 22:444-8.
8. Sanchez-Roman J, Wichmann I, Salaberri J et al. Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis 1993; 52:534-8.
9. Ueki A, Yamaguchi M, Ueki H et al. Polyclonal human T-cell activation by silicate in vitro. Immunology 1994; 82:332-5.
10. Tapia FJ, Goihman YM, Caceres DG et al. Leukocyte immunophenotypes in bronchoalveolar lavage fluid and peripheral blood of paracoccidioidomycosis, sarcoidosis and silicosis. Histol Histopathol 1991; 6:395-402.
11. Miyawaki T, Uehara T, Nibu R et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 11:3753-8.
12. Knipping E, Krammer PH, Onel KB et al. Levels of soluble Fas/APO-1/ CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38:1735-7.
13. Goel N, Ulrich DT, St Clair EW et al. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995; 38:1738-43.
14. Wu J, Wilson J, He J et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98:1107-13.
15. Seishima M, Takemura M, Saito K et al. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Clin Chem 1996; 42:1911-4.
16. Bramwell B. Diffuse scleroderma: its frequency; its occurence in stonemasons; its treatment by fibrinolysin-elevations of temperature due to fibrinolysin injections. Ed Med J 1914; 12:387-401.
17. Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 1953; 8:29-37.
18. Erasmus LD. Scleroderma in gold-miners on the Witwatersrand with particular reference to pulmonary manifestations. S Afr J Lab Clin Med 1958; 3:209-31.
19. Rodnan GP, Benedek TG, Medsger TA Jr et al. The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. Ann Intern Med 1967; 66:323-34.
20. Uber CL, McReynolds RA. Immunotoxicology of silica. Crit Rev Toxicol 1982; 10:303-19.
21. Parkes WR. Fundamentals of pathogenesis and pathology. In: Parkes WR ed. Occupational lung disorders, 2nd edn. London: Butterworths, 1982: 54-88.
22. Haslam LP. Basic immunology and immunopathology. In: Parkes WR ed. Occupational lung disorders, 3rd edn. London: Butterworth Heinemann, 1994: 50-99.
23. Rustin MHA, Bull HA, Ziegler V et al. Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 1990; 123:725-34.
24. + T cells by chrysotile asbestos in vitro. Cancer Lett 1992; 66:99-106.
25. + T cells in mice tolerant to staphylococcus aureus enterotoxin B. Nature 1991; 349:245-8.